LIVTENCITY β TAKEDA PHARMS USA, approved 2025-11-21 (NDA215596).
2,587 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System β they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.